Table Graph
      published meta-analysis   sensitivity analysis   studies

anticoagulant, curative dose in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.88 [0.64; 1.20] 0.88[0.64; 1.20]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,226NAnot evaluable clinical improvement (28-day)detailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.27 [1.03; 1.57] 1.27[1.03; 1.57]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,219NAnot evaluable death or ventilationdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 0.82 [0.63; 1.07] 0.82[0.63; 1.07]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,231NAnot evaluable Major bleedingdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 1.80 [0.88; 3.67] 1.80[0.88; 3.67]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 202110%2,227NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-04-19 11:12 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 830 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons